Economic evaluation of prevention; further evidence
2007
This report is the third in a series of reports that aim to identify
cost-effective preventive interventions that have not yet been diffused
into the Dutch health care system or into a public health setting.
In the first part of this report, five new interventions are presented
and at the same time, renew the information on cost-effectiveness and
implementation issues for six interventions that were described in less
detail in our first report. For all eleven interventions, brief
information on the magnitude and character of the health problem is
presented, along with information on the intervention, its
cost-effectiveness, and issues related to the transferability of foreign
study results to the Dutch situation and possible future implementation
of the intervention in the Netherlands. There is strong evidence for
cost-effectiveness for (1) screening for neonatal group beta
streptococcal infections, (2) fluoridation of drinking water, (3)
mandatory folic acid fortification of staple foods, (4) vaccination
against varicella zoster virus and (5) stop smoking interventions.
Evidence on cost-effectiveness is moderate for (6) influenza vaccination
of healthy working adults, (7) rotavirus vaccination of newborns, (8)
universal hepatitis B vaccination, (9) pertussis vaccination of
adolescents, (10) human papilomavirus vaccination of adolescents, and
(11) pneumococcal vaccination of elderly persons. However, for all
interventions, we conclude that the transferability of the results to the
Dutch situation is poor and more research is needed to investigate
cost-effectiveness in the Dutch context. With respect to implementation
opportunities, it is anticipated that screening for neonatal group beta
streptococcal infections, pertussis vaccination of adolescents, influenza
vaccination of healthy working adults and pneumococcal vaccination of
elderly persons is feasible.
In the second part of this report, the cost-effectiveness was modelled
for two interventions that were shown to be cost-effective in an
international context and had no major barriers for implementation in the
Netherlands. The two interventions were the prevention of recurrent
depression by maintenance cognitive behavioural therapy (mCBT), and the
prevention of chronic diseases by pharmacologic treatment of obesity.
The analyses showed that mCBT is more cost-effective than usual care,
which is prescription of anti-depressive medication. Compared to usual
care, mCBT has a cost-effectiveness ratio of 15,000 per QALY. The
cost-effectiveness of providing pharmacologic treatment (Orlistat) in
combination with a diet is relatively high. Costs per QALY gained are
62,000 for Orlistat plus diet compared to diet alone. The modelling
study underlines the importance of performing Dutch specific
cost-effectiveness analyses and confirms the low transferability of
foreign studies to the Dutch situation as was shown in the first part of
the report.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI